Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD PromactaⓇ - Thrombopoetin receptor agonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03025698 (CETB115E2201) Refractory or relapsed severe aplastic anemia Phase 2 60 PK of eltrombopag at steady state in pediatric patients with SAA Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Final CSR: 2025 TBD NCT03988608 (CETB115E2202) Refractory or relapsed severe aplastic anemia Phase 2 20 Hematologic response rate rate up to 26 weeks of treatment Eltrombopag 25 mg film-coated tablets Chinese patients with refractory or relapsed severe aplastic anemia Primary: 2021; Final: 2023 TBD 123 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation